Regeneron Reports Phase 3 extension Data for Rucaparib in Obesity

Regeneron today announced Phase 3 extension results for rucaparib in patients with obesity. The study demonstrated that rucaparib demonstrates safety and tolerability compared to standard of care or placebo. These results provide important insights into the treatment of obesity and support the continued development of rucaparib in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.